Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study-Reference-Cited by-同舟云学术

Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study

Published:2009-08 Issue:2 Volume:83 Page:99-107
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Wahlin Anders,Billström Rolf,Björ Ove,Ahlgren Tomas,Hedenus Michael,Höglund Martin,Lindmark Anders,Markevärn Berit,Nilsson Bo,Sallerfors Bengt,Brune Mats

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2009.01256.x/fullpdf

Reference24 articles.

1. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties;Wheatley;Br J Haematol,1999

2. Intensive postremission chemotherapy in adults with acute myeloid leukemia;Mayer;N Engl J Med,1994

3. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups;Zittoun;N Engl J Med,1995

4. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA/AML-10 trial;Suciu;Blood,2003

5. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial;Burnett;Br J Haematol,2002

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence on therapeutic outcome of platelet count at diagnosis in patients with de novo non-APL acute myeloid leukemia;BMC Cancer;2023-10-24

2. Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single‐arm, phase 2 trial ( RJ‐AML 2014);American Journal of Hematology;2021-11

3. Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A^mut;Cancer Management and Research;2018-08

4. Development and Validation of a Novel RNA Sequencing–Based Prognostic Score for Acute Myeloid Leukemia;JNCI: Journal of the National Cancer Institute;2018-03-01

5. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling;Leukemia;2017-02-07